An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects With Relapsed or Refractory, CD22-Positive, Follicular B-Cell Non-Hodgkin's Lymphoma.

Trial Profile

An Open-Label, Randomized, Phase 3 Study of Inotuzumab Ozogamicin (CMC-544) Administered in Combination With Rituximab Compared to a Defined Investigator's Choice Therapy in Subjects With Relapsed or Refractory, CD22-Positive, Follicular B-Cell Non-Hodgkin's Lymphoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Oct 2014

At a glance

  • Drugs Inotuzumab ozogamicin (Primary) ; Cyclophosphamide; Dexamethasone; Fludarabine; Mitoxantrone; Prednisolone; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Jun 2012 Additional trial location (United Kingdom) added as reported by European Clinical Trials Database.
    • 17 Jun 2012 Results presented at the 17th Congress of the European Haematology Association.
    • 21 Apr 2012 Additional trial location added as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top